Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QR-421a in advanced USH2A exon 13 retinitis pigmentosa
NL-OMON52147Phase 3Completed
- Sponsor
- ProQR Therapeutics
- Start
- Jul 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ultevursen in retinitis pigmentosa (RP) and Usher syndrome type 2 (USH2) (3 arms), sponsored by ProQR Therapeutics. Primary endpoint: Change from baseline in best corrected visual acuity. Started Jul 2022; status: completed.
02
Drugs
ultevursen
03
Conditions
retinitis pigmentosa (RP)Usher syndrome type 2 (USH2)
Beyond the preview
Go deeper on NL-OMON52147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52147.